Ikumi Kitazono

EGFR and TP53 mutations refine prognostic stratification of IDH-wildtype astrocytomas, not elsewhere classified

Abstract IDH -wildtype astrocytomas of histological grade 2 or 3 without the WHO 2021 molecular criteria for glioblastoma— TERT promoter mutation, EGFR amplification, or combined whole-chromosome 7 gain and 10 loss (+ 7/– 10)—are designated “Not Elsewhere Classified” (NEC), a res...